5:21 PM
 | 
Mar 21, 2018
 |  BC Innovations  |  Translation in Brief

Mining marine metabolites

Sirenas, BMS use AI to discover small molecule microbiome metabolites

Bristol-Myers Squibb Co. (NYSE:BMY) is tapping Sirenas LLC’s AI platform Atlantis to discover microbiome metabolites for immuno-oncology.

Atlantis applies data mining, computational modeling and machine learning technology to screen microbiome-derived metabolites against cellular and biochemical disease models, which then become the basis for synthetic chemistry campaigns to yield immuno-modulatory candidates.

The company’s metabolites are mainly derived from the microbiomes of marine organisms, such as sponges, cyanobacteria and algae.

Chairman and...

Read the full 333 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$100 USD
More Info >